Brian Kenneth Kay
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$3.4MFederal grants as PI10 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
10 awards · $3.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 1, 2026 | NIH | SBIR Phase II Generating phosphobodies to activated protein kinases | $1.2M | Tango Biosciences Inc. |
| Aug 24, 2026 | NIH | SBIR Phase I Peptide Glues | $333K | Tango Biosciences Inc. |
| Jul 2, 2025 | NIH | SBIR Phase I The Avidimer Platform - a molecular toolbox to accelerate proximity research and drug discovery | $314K | Tango Biosciences Inc. |
| May 1, 2023 | NIH | SBIR Phase I High-throughput profiling of proteases with phage and arrays | $257K | Tango Biosciences Inc. |
| Apr 12, 2023 | NIH | SBIR Phase I Generating fast-on rate reagents for lateral flow assays to detect HCV | $276K | Tango Biosciences Inc. |
| Apr 15, 2022 | NIH | SBIR Phase I Building a pipeline to generate affinity reagents to phosphothreonine epitopes | $223K | Tango Biosciences Inc. |
| Dec 22, 2020 | NIH | SBIR Phase I Building a Toolbox to Study the SARS-CoV-2 Proteome | $222K | Tango Biosciences Inc. |
| Jul 21, 2020 | NIH | STTR Phase I Array Based Affinity Selection | $183K | Tango Biosciences Inc. |
| Aug 27, 2019 | NIH | STTR Phase I Array Based Affinity Selection | $224K | Tango Biosciences Inc. |
| Mar 19, 2018 | NIH | STTR Phase I Generating sandwich assays through MegaSTAR | $224K | Tango Biosciences Inc. |
Peer ranks
Federal funding#510
Awards as PI#128
Patents#273
Companies
- Tango Biosciences Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.